AXIM (AXIM Biotechnologies) Shares Outstanding (EOP): 332.96 Mil (As of Jun. 2025)


What is AXIM Biotechnologies Shares Outstanding (EOP)?

AXIM Biotechnologies AXIM -16.00% Shares Outstanding (EOP) is 332.96 Mil as of Jun. 2025. The stock has 7 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. AXIM Biotechnologies's shares outstanding for the quarter that ended in Jun. 2025 was 332.96 Mil.

AXIM Biotechnologies's quarterly shares outstanding increased from Mar. 2025 (332.76 Mil) to Jun. 2025 (332.96 Mil). It means AXIM Biotechnologies issued new shares from Mar. 2025 to Jun. 2025 .

AXIM Biotechnologies's annual shares outstanding increased from Dec. 2023 (245.93 Mil) to Dec. 2024 (318.90 Mil). It means AXIM Biotechnologies issued new shares from Dec. 2023 to Dec. 2024 .


AXIM Biotechnologies  (OTCPK:AXIM) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


AXIM Biotechnologies Shares Outstanding (EOP) Related Terms


AXIM Biotechnologies Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for AXIM Biotechnologies's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AXIM Biotechnologies Shares Outstanding (EOP) Chart

AXIM Biotechnologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 125.33 138.10 192.44 245.93 318.90

AXIM Biotechnologies Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 278.43 294.46 318.90 332.76 332.96

AXIM vs HEPA, SCNI, BZYR: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AXIM Biotechnologies Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Shares Outstanding (EOP) falls into.



AXIM Biotechnologies Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 332.96 Mil mean?
AXIM Biotechnologies (AXIM) has a Shares Outstanding (EOP) of 332.96 Mil as of Jun. 2025. The total shares a company has outstanding, at period-end. View historical data on AXIM Biotechnologies and its competitors.
Is AXIM Biotechnologies' Shares Outstanding (EOP) too high?
AXIM Biotechnologies' current Shares Outstanding (EOP) is 332.96 Mil.
How does AXIM Biotechnologies' Shares Outstanding (EOP) compare to HEPA and SCNI?
AXIM Biotechnologies' Shares Outstanding (EOP) of 332.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on AXIM Biotechnologies and its competitors. AXIM Biotechnologies's current Shares Outstanding (EOP) is 332.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AXIM Biotechnologies stock overvalued right now?
AXIM Biotechnologies (AXIM) has a current Shares Outstanding (EOP) of 332.96 Mil. The current Shares Outstanding (EOP) is 332.96 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For AXIM Biotechnologies (AXIM), the current Shares Outstanding (EOP) is 332.96 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.